Completed PHASE2 INTERVENTIONAL 2-arm NCT00420511

Beta-Cell Function and Sitagliptin Trial (BEST) (BEST)

A Randomized Controlled Pilot Study Assessing the Effect of Sitagliptin on the Preservation of Beta-Cell Function in Patients With Type 2 Diabetes

Sponsor: Merck Sharp & Dohme LLC

Conditions Type 2 Diabetes Mellitus

Interventions Placebo Sitagliptin metformin

Updated 7 times since 2017 Last updated: Dec 28, 2011 Started: Jan 31, 2007 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Type 2 Diabetes Mellitus, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2022 — Jul 2024 [monthly]

Completed PHASE2
Dec 2021 — Jun 2022 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Data source: Samuel Lunenfeld Research Institute, Mount Sinai Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada